Oct 5, 2026 · 1h 27m
Lipid guidelines shift prevention toward lifetime risk
#541 A Walk Through the 2026 Lipid Management Guidelines
The episode shows how clinicians can turn risk enhancers, advanced lipid testing, and coronary calcium into more personalized prevention decisions.
- 1Lifetime ASCVD risk and factors such as preeclampsia can matter more than a young patient’s short-term risk score.
- 2ApoB, lipoprotein(a), and coronary calcium can refine treatment discussions, but each test has a specific role and limitation.
- 3Statin intolerance and persistent LDL elevation call for structured rechallenge, combination therapy, and specialist referral when complexity warrants.
Don't miss
Daniel Edmundowicz explains how gestational diabetes and preeclampsia should remain visible in the cardiovascular risk record, even years later.
The brief
Daniel Edmundowicz joins Matthew F. Watto, Paul Nelson-Williams, and Deborah Gorth to examine lipid management through cases rather than isolated lab values.
A 43-year-old with gestational diabetes, preeclampsia, hypertension, and mildly abnormal lipids illustrates why lifetime ASCVD risk can outweigh a reassuring 10-year estimate.
The discussion weighs LDL and non-HDL targets, ApoB, lipoprotein(a), and coronary calcium, emphasizing that each can sharpen shared decisions without replacing clinical judgment.
When treatment becomes difficult, the episode moves from statin selection and myalgia management to ezetimibe, bempedoic acid, PCSK9 therapy, and inclisiran.
A second case with LDL of 192 raises familial hypercholesterolemia, family screening, early treatment, and the point at which lipid-specialist input becomes valuable.